Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2022
Availability of new medicines in the US and Germany (2004 - 2018)
30 August 2022 - In this cohort study comparing 599 medicine approvals in the US and Germany between 2004 and 2018, ...
Posted by Michael Wonder on 01 Sep 2022
ACE publishes another tranche of technology guidances (August 2022)
31 August 2022 - Six technology guidance documents were published yesterday. ...
Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits ...
Posted by Michael Wonder on 31 Aug 2022
Amneal announces submission of new drug application to the US FDA for IPX203 for the treatment of Parkinson’s disease
31 August 2022 - IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients ...
Posted by Michael Wonder on 31 Aug 2022
Governor Ron DeSantis announces lawsuit against Biden Administration’s reckless delay of Canadian Prescription Drug Importation Program
31 August 2022 - Today, Governor Ron DeSantis announced a lawsuit against the US FDA in response to their unreasonable delay ...
Posted by Michael Wonder on 31 Aug 2022
Kidney disease drug dapagliflozin added to Pharmaceutical Benefits Scheme
31 August 2022 - Lachlan Ross describes his more than a decade-long battle with kidney failure as "very long, and very ...
Posted by Michael Wonder on 31 Aug 2022
Schedule of Pharmaceutical Benefits - 1 September 2022
1 September 2022 - The September 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Aug 2022
New Zealand Pharmaceutical Schedule - 1 September 2022 update
1 September 2022 - The September 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2022
FDA approves first treatment for acid sphingomyelinase deficiency, a rare genetic disease
31 August 2022 - Today, the US FDA approved Xenpozyme (Olipudase alfa) for intravenous infusion in paediatric and adult patients with ...
Posted by Michael Wonder on 31 Aug 2022
Aquestive Therapeutics receives FDA tentative approval for Libervant (diazepam) buccal film
31 August 2022 - Libervant US market access currently subject to the expiration of Valtoco orphan drug market exclusivity. ...
Posted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 31 Aug 2022
Scilex announces that the FDA has granted fast track designation for SP-103 (lignocaine 5.4% topical system), next generation triple strength formulation of ZTlido for the treatment of acute low back pain
30 August 2022 - According to the CDC in 2020, low back pain was the most common type of pain reported ...
Posted by Michael Wonder on 31 Aug 2022
Brolucizumab for treating diabetic macular oedema
31 August 2022 - NICE has published evidence-based recommendations on the use of brolucizumab (Beovu) for the treatment of adults ...
Posted by Michael Wonder on 30 Aug 2022
Can the Inflation Reduction Act bring down drug prices?
30 August 2022 - The legislation signed by President Joe Biden on August 16 empowers Medicare to negotiate the prices of ...
Posted by Michael Wonder on 30 Aug 2022
First new kidney treatment in 20 years delays dialysis and transplant
31 August 2022 - Kidney disease is Australia’s silent killer, with nine in 10 patients unaware they have it until too ...